ReachRxResearch
Home
Research
Sign Up
FDA Approves First Freeze-Dried Plasma Product in the US
Back to Research Hub
  1. Home
  2. Research Hub
  3. FDA Approves First Freeze-Dried Plasma P…

FDA Approves First Freeze-Dried Plasma Product in the US

JAMA·August 21
Medicine, General & InternalPractice changingHemorrhageNews/Regulatory AnnouncementBlood ProductFreeze-Dried PlasmaAdult

Summary

View source

What was studied

FDA approval of the first freeze-dried plasma product in the United States, intended for transfusion in adult patients when other plasma products are unavailable (e.g., combat zones, rural areas, disaster settings).

Key findings

The FDA approved a freeze-dried plasma product that is stable at room temperature and can be rapidly reconstituted, unlike traditional plasma which requires freezing and thawing.

Study limitations

This is a brief news item; no clinical trial data, efficacy outcomes, safety data, or sample sizes are reported in the available text.

Clinical implications

Clinicians in austere or resource-limited settings (military, rural, disaster response) may now have access to a room-temperature-stable plasma product that does not require a cold chain or thawing before use.

Caveats

  • No brand or generic name for the approved product is provided in the available text
  • The freeze-dried plasma product is specifically indicated for adults when other plasma products are not available; its role as a first-line product in well-resourced settings is not established
  • This is a short regulatory news brief, not a primary research article — no efficacy, safety, or trial data are available from the source text

Related Questions

Explore related topics

What are the clinical outcomes of freeze-dried plasma compared to fresh frozen plasma in trauma patients?How does lyophilized plasma perform in prehospital or military trauma settings?What are the storage and reconstitution requirements for the newly FDA-approved freeze-dried plasma product?

Publication Details

Year
2026
Journal
JAMA
Source
View article
Keep scrolling
More content below.
Up Next